

**Request for information on the use of non-human primates in safety/efficacy testing**

The Animals in Science Committee (ASC) has a role to provide independent, balanced, and objective advice to the Minister in areas relating to the use of animals in scientific procedures.  Project Licences are referred for additional review by the ASC if they fall into certain categories (e.g., the use of non-human primates in severe procedures). The ASC is currently undertaking a strategic review of licences that use non-human primates (NHP) in other procedures (e.g., mild and moderate): for example, in service licences for safety/efficacy testing, or provision of blood/tissue.

To help with evidence-gathering, the ASC would be grateful to hear from organisations with an interest in this field.

Please submit the completed questionnaire to asc.secretariat@homeoffice.gov.uk at the latest by **2 October 2023.**

**Questions**

1. Name of organisation

Answer below:

1. Please provide your views and comments on the most important roles and responsibilities of the designated establishment, particularly the project licence holder and the local Animal Welfare and Ethical Review Body, in ensuring that each use of animals in projects relating to the safety/efficacy testing of potential new medicines and other substances has been adequately justified, both scientifically and ethically.

Answer below:

1. Please provide your views and comments on the most important roles and responsibilities of

the regulator, the Animals in Science Regulation Unit, in ensuring that each use of animals in projects relating to the safety/efficacy testing of potential new medicines and other substances has been adequately justified, both scientifically and ethically.

Answer below:

1. Please provide your views and comments on how you think the Harm-Benefit Analysis should be applied and undertaken for project applications under the Animals (Scientific Procedures) Act 1986 (as amended) in the categories of safety/efficacy testing of potential new medicines and other substances.

Answer below:

1. Please provide your views and comments relating to potential opportunities, along with the locus of responsibility, for further implementing the 3Rs relating to the use of NHPs for the safety/efficacy testing of potential new medicines and other substances.

Answer below: